Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma

Tumor Biology

Volumn 27, Issue 4, 2006, Pages 187-194

  Breen, Elizabeth Crabb ^a   Fatahi, Sepi ^a   Epeldegui, Marta ^a   Boscardin, W John ^b   Detels, Roger ^b   Martínez Maza, Otoniel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; B lymphocyte; Cytokine; HIV; Non Hodgkin's lymphoma; sCD30

Indexed keywords

BIOLOGICAL MARKER; CD23 ANTIGEN; CD27 ANTIGEN; CD30 ANTIGEN; CXCL13 CHEMOKINE; HERMES ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN DETECTION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SERODIAGNOSIS; T LYMPHOCYTE ACTIVATION;

EID: 33646718357     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093022     Document Type: Article

References (25)

1. Knowles DM: Immunophenotypic markers useful in the diagnosis and classification of hematopoietic neoplasms; in Knowles DM (ed): Neoplastic Hematopathology. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 93-226.
2. Croft M: Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-620.
3. Younes A, Aggarwall BB: Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003;98:458-467.
4. Nadali G, Vinante F, Stein H, Todeschini G, Tecchio C, Morosato L, Chilosi M, Menestrina F, Kinney MC, Greer JP, Latza U, Perona G, Pizzolo G: Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol 1995;13:1355-1360.
5. Zinzani PL, Pileri S, Bendandi M, Buzzi M, Sabattini E, Ascani S, Gherlinzoni F, Magagnoli M, Albertini P, Tura S: Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 1998;16:1532-1537.
6. Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, Musto P, Di Renzo N, Carotenuto M, Chilosi M, Krampera M, Pizzolo G: Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998;91:3011-3016.
7. Zanotti R, Trolese A, Ambrosetti A, Nadali G, Visco C, Ricetti MM, Benedetti F, Pizzolo G: Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol 2002;13:1908-1914.
8. Knowles DM: Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2003;17:785-820.
9. Martínez-Maza O, Widney D, van der Meijden M, Knox R, Echeverri A, Breen EC, Magpantay L, Miles S: Immune dysfunction and the pathogenesis of AIDS-associated non-Hodgkin's lymphoma. Mem Inst Oswaldo Cruz 1998;93:373-381.
10. Detels R, Phair JP, Saah AJ, Rinaldo CR Jr, Munoz A, Kaslow RA, Seminara D, Schrager L, Vermund S: Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. J Epidemiol 1992;2(suppl):S11-S19.
11. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
12. Yawetz S, Cumberland WG, van der Meyden M, Martínez-Maza O: Elevated serum levels of soluble CD23 (sCD23) precede the appearance of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma. Blood 1995;85:1843-1849.
13. Breen EC, van der Meijden M, Cumberland W, Kishimoto T, Detels R, Martínez-Maza O: The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999;92:293-299.
14. Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, Demidem A, Trevisan C, Taylor J, Detels R, Martínez-Maza O: Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999;93:114-123.
15. Schroeder J, Saah AJ, Hoover DR, Margolick JB, Ambinder RF, Martínez-Maza O, Crabb Breen E, Jacobson LP, Variakojis D, Rowe DT, Armenian HK: Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 1999;8:979-984.
16. Breen EC, Boscardin WJ, Detels R, Jacobson L, Smith MW, O'Brien SJ, Chmiel JS, Rinaldo CR, Lai S, Martínez-Maza O: Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter-592 C/C genotype. Clin Immunol 2003;109:119-129.
17. Breen EC, Epeldegui M, Boscardin WJ, Widney DP, Detels R, Martínez-Maza O: Elevated levels of soluble CD44 (sCD44) precede the development of AIDS-associated NHL. AIDS 2005;19:1711-1712.
18. Widney DP, Breen EC, Boscardin WJ, Smith JB, Detels R, Martínez-Maza O: Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res, in press.
19. Lane HC, Fauci AS: Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol 1985;3:477-500.
20. Pizzolo G, Vinante F, Morosato L, Nadali G, Chilosi M, Gandini G, Sinicco A, Raiteri R, Semenzato G, Stein H, Perona G: High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of the progression to AIDS. AIDS 1994;8:741-745.
21. Sabin CA, Bofill M, Phillips AN, Elford J, Janossy G, Lee CA: Relation between soluble CD30 levels measured soon after HIV seroconversion and disease progression in men with hemophilia. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:279-283.
22. Rizzardi GP, Tambussi G, Barcellini W, Capiluppi B, Clerici E, La Maestra L, Lillo F, Pantaleo G, Lazzarin A: Soluble CD30, tumour necrosis factor (TNF)-α, and TNF receptors in primary HIV-1 infection: relationship with HIV-1 RNA, clinical outcome and early antiviral therapy. J Biol Regul Homeost Agents 1997;11:43-49.
23. Schroeder J, Saah A, Ambinder RF, Martínez-Maza O, Crabb Breen E, Variakojis D, Margolick JB, Jacobson LP, Rowe DT, Hoover DR: Serum sCD23 level in patients with AIDS-related non-Hodgkin's lymphoma is associated with the absence of EBV in tumor tissue. Clin Immunol 1999;93:239-244.
24. Keane NM, Price P, Lee S, Stone SF, French MA: An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 2001;126:111-116.
25. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G: CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995;57:726-730.